Literature DB >> 11273235

GMC's proposals for revalidation. Purpose of revalidation process must be agreed on.

D Newble.   

Abstract

Mesh：

Year:  2001        PMID： 11273235      PMCID： PMC1119585     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

Review 1.  Revalidation in the United Kingdom: general principles based on experience in general practice.

Authors:  L Southgate; M Pringle
Journal:  BMJ       Date:  1999-10-30

2.  Validity of final examinations in undergraduate medical training.

Authors:  C van der Vleuten
Journal:  BMJ       Date:  2000-11-11

3.  GMC's proposals for revalidation would not be accurate, economical, or fair.

Authors:  R Wakeford
Journal:  BMJ       Date:  2000-11-11

4.  Educational portfolios in the assessment of general practice trainers: reliability of assessors.

Authors:  J Pitts; C Coles; P Thomas
Journal:  Med Educ       Date:  1999-07       Impact factor: 6.251

5.  LMSSA: a back door entry into medicine?

Authors:  R Wakeford
Journal:  Br Med J (Clin Res Ed)       Date:  1987-04-04

6.  MRCGP pass rate by medical school and region of postgraduate training. Royal College of General Practitioners.

Authors:  R Wakeford; J Foulkes; C McManus; L Southgate
Journal:  BMJ       Date:  1993-08-28

7.  Use of peer ratings to evaluate physician performance.

Authors:  P G Ramsey; M D Wenrich; J D Carline; T S Inui; E B Larson; J P LoGerfo
Journal:  JAMA       Date:  1993-04-07       Impact factor: 56.272
  7 in total
  3 in total

1.  GMC: approaching the abyss.

Authors:  R Smith
Journal:  BMJ       Date:  2001-05-19

2.  Revalidation: the purpose needs to be clear.

Authors:  Tim van Zwanenberg
Journal:  BMJ       Date:  2004-03-20

3.  The Evolving Purposes of Medical Revalidation in the United Kingdom: A Qualitative Study of Professional and Regulatory Narratives.

Authors:  Abigail Tazzyman; Jane Ferguson; Kieran Walshe; Alan Boyd; John Tredinnick-Rowe; Charlotte Hillier; Samantha Regan De Bere; Julian Archer
Journal:  Acad Med       Date:  2018-04       Impact factor: 6.893
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.